Serum BAFF level and its correlations with various disease parameters in patients with systemic sclerosis and systemic lupus erythematosus

Lipsky, 2001, Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity, Nat Immunol, 2, 764, 10.1038/ni0901-764 Cassese, 2001, Inflamed kidneys NZB/W mice are a major site for the homeostasis of plasma cells, Eur J Immunol, 31, 2726, 10.1002/1521-4141(200109)31:9<2726::AID-IMMU2726>3.0.CO;2-H Mackay, 2002, BAFF a fundamental survival factor for B cells, Nat Rev Immunol, 2, 465, 10.1038/nri844 Moore, 1999, BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator, Science, 285, 260, 10.1126/science.285.5425.260 Thompson, 2001, A newly identified TNF receptor that specifically interact with BAFF, Science, 293, 2108, 10.1126/science.1061965 Gross, 2000, TACI and BCMA are receptors for TNF homologue implicated in B-cell autoimmune disease, Nature, 404, 995, 10.1038/35010115 Yoshimoto, 2006, Aberrant expression of BAFF in T cells of systemic lupus erythematosus, which is recapitulated by a human T cell line, Loucy, Int Immunol, 18, 1189, 10.1093/intimm/dxl053 Chu, 2009, Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus, Arthritis Rheum, 60, 2083, 10.1002/art.24628 Szodoray, 2005, The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjögren's syndrome, Scand J Immunol, 62, 421, 10.1111/j.1365-3083.2005.01688.x Von Feldt, 1995, Systemic lupus erythematosus. Recognizing its various presentations, Postgrad Med, 97, 79, 10.1080/00325481.1995.11945982 Roschke, 2002, BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases, J Immunol, 169, 4314, 10.4049/jimmunol.169.8.4314 Cheema, 2001, Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases, Arthritis Rheum, 44, 1313, 10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S Zhang, 2001, Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus, J Immunol, 166, 6, 10.4049/jimmunol.166.1.6 Stohl, 2003, B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations, Arthritis Rheum, 48, 3475, 10.1002/art.11354 Matsushita, 2007, Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases, Exp Dermatol, 16, 87, 10.1111/j.1600-0625.2006.00485.x Hasegawa, 2010, B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis, J Dermatol, 37, 3, 10.1111/j.1346-8138.2009.00763.x van Laar, 2010, B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis, Arthritis Res Ther, 12, 112, 10.1186/ar2977 Matsushita, 2006, Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes, Arthritis Rheum, 54, 192, 10.1002/art.21526 ARA: Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581–90. Le Roy, 1988, Scleroderma (systemic sclerosis): classification, subsets and pathogenesis, J Rheumatol, 15, 202 Tan, 1982, The 1982 revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum, 25, 1271, 10.1002/art.1780251101 Clements, 1995, Inter- and intraobserver variability of total skin thickness score (modified Rodan TSS) in systemic sclerosis, J Rheumatol, 22, 1281 Liang, 1989, Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus, Arthritis Rheum, 32, 1107, 10.1002/anr.1780320909 Gladman, 1996, The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus, Arthritis Rheum, 39, 363, 10.1002/art.1780390303 Bosello, 2007, BAFF and rheumatic autoimmune disorders: implications for disease management and therapy, Int J Immunopathol Pharmacol, 20, 1, 10.1177/039463200702000101 Matsushita, 2007, Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF, J Rheumatol, 34, 2056 Saito, 2002, CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse, J Clin Invest, 109, 1453, 10.1172/JCI0215078 Becker-Merok, 2006, B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time, Lupus, 15, 570, 10.1177/0961203306071871 Zhao, 2010, Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients, Lupus, 19, 1534, 10.1177/0961203310375268 Sellam, 2007, Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus, Ann Rheum Dis, 66, 790, 10.1136/ard.2006.065656 Ramanujam, 2008, BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?, Immunol Rev, 223, 156, 10.1111/j.1600-065X.2008.00625.x Sanz, 2010, B cells as therapeutic targets in SLE, Nat Rev Rheumatol, 6, 326, 10.1038/nrrheum.2010.68 Stohl, 2004, A therapeutic role for BLyS antagonists, Lupus, 13, 317, 10.1191/0961203304lu1019oa Kayagaki, 2002, BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-B2, Immunity, 17, 515, 10.1016/S1074-7613(02)00425-9 Baker, 2003, Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator, Arthritis Rheum, 48, 3253, 10.1002/art.11299 Furie, 2008, Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus, Arthritis Res Ther, 10, R109, 10.1186/ar2506